261 related articles for article (PubMed ID: 28336778)
1. The Predictive Value of Early In-Treatment
Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
[No Abstract] [Full Text] [Related]
2. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
3. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
4. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
5. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
6.
Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
[TBL] [Abstract][Full Text] [Related]
7. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
8. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
10. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
[TBL] [Abstract][Full Text] [Related]
11. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
12. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
14. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
15. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
Lee HY; Choi WH; Yoo IR; Park JK; Sung SW; Kim YS; Kang JH
Asia Pac J Clin Oncol; 2020 Feb; 16(1):70-74. PubMed ID: 31782256
[TBL] [Abstract][Full Text] [Related]
17. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer.
Han EJ; Yang YJ; Park JC; Park SY; Choi WH; Kim SH
Nucl Med Commun; 2015 Dec; 36(12):1187-94. PubMed ID: 26375438
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
Ordu C; Selcuk NA; Akosman C; Eren OO; Altunok EC; Toklu T; Oyan B
Asian Pac J Cancer Prev; 2015; 16(1):321-6. PubMed ID: 25640373
[TBL] [Abstract][Full Text] [Related]
20. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Banna GL; Anile G; Russo G; Vigneri P; Castaing M; Nicolosi M; Strano S; Gieri S; Spina R; Patanè D; Calcara G; Fraggetta F; Marletta F; Stefano A; Ippolito M
Oncology; 2017; 92(1):39-47. PubMed ID: 27832654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
